Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0149514 (bronchitis)
 6,902 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A cross-sectional epidemiological investigation of the health status of 261 people from 85 private households previously treated with chlordane for termite control was conducted to assess potential human health effects. When sinusitis, bronchitis, and migraine responses were compared to measured indoor air levels of chlordane in categories designated as low (less than 1 microgram/m3), medium (1-5 micrograms/m3), and high (greater than 5 micrograms/m3), a dose-response relationship was found after controlling individually and simultaneously for age, sex, and smoking. Homes studied in this investigation having a proper chlordane application were observed to have chlordane air levels exceeding acceptable exposure limits.
 ...
PMID:A preliminary study of potential human health effects in private residences following chlordane applications for termite control. 326 84

Erythromycin acistrate (EA)--a new ester of erythromycin--was compared with erythromycin base as enterocoated pellets in capsules (EB enterocapsules) and enterocoated tablets of erythromycin base (EB enterotablets) in the treatment of respiratory tract infections. The present double-blind, multicentre study, conducted in eight occupational health centres, included 474 patients; 236 treated with EA, 117 with EB enterocapsules and 121 with EB enterotablets. The diagnoses included tonsillitis, sinusitis, otitis media, bronchitis and pneumonia. The patients were examined on admission and at the end of the treatment. The dosage of EA was 400 mg tid and that of the two erythromycin base preparations 500 mg tid. The treatment was given for seven to 14 days. In the EA-group, 97% of patients were clinically cured by the end of the treatment, while the cure rates for EB enterocapsules and EB enterotablets were 95% and 94%, respectively. Gastrointestinal side effects were reported by 36% of the patients on EA, 54% on EB enterocapsules and 50% on EB enterotablets. Discontinuations due to adverse effects occurred in 8% in the EA, in 21% in the EB enterocapsule and in 12% in the EB enterotablet groups. All three preparations were thus equally effective, but EA caused statistically significantly less gastrointestinal side effects overall (P less than 0.01), especially nausea (P less than 0.01) and abdominal pain (P less than 0.05), than the two formulations containing erythromycin base. Also discontinuations due to side effects occurred statistically significantly less frequently in the EA-group.
 ...
PMID:Treatment of respiratory tract infections with erythromycin acistrate and two formulations of erythromycin base. 339 72

A case of Young's syndrome is described presenting with obstructive azoospermia, sinusitis, otitis media and bronchitis. It is essential to examine ciliary function and ultrastructure in order to make this diagnosis.
 ...
PMID:Young's syndrome (a case report). 339 45

The effects of household exposure to cigarette smoke on hospitalization and incidence of respiratory illness were examined among 2227 children at Chang-Ning District, Shanghai Municipality, People's Republic of China. The passive smoking quantity was estimated by total daily cigarette consumption of family members and number of cigarettes smoked in the home. No mothers who smoked were found. A significant dose-response relationship of passive smoking to hospitalization for respiratory illness during the children's first 18 months of life was found, for which no confounding factors were discovered. The incidence density ratio of hospitalization for respiratory illness was 2.1 for children living in families including people who smoked 20 or more cigarettes a day compared with those living in non-smoking families. The children appeared to be more vulnerable in the first six months of life than in the 7-18 month period, and those with lower birth weight and the artificially fed were more susceptible. The cumulative incidence of bronchitis or pneumonia increased significantly with increasing cigarette smoking of family members, which persisted when sex, birthweight, nursery care, father's education, coal for cooking, and adult cases with chronic respiratory disease were taken into account. Family smoking status was not found to be significantly associated with the incidence of asthma, whooping cough, sinusitis and measles.
 ...
PMID:Chang-Ning epidemiological study of children's health: I: Passive smoking and children's respiratory diseases. 340 30

Tolerance, clinical effects and kinetics of an unmodified immunoglobulin preparation for intravenous use were investigated in 4 patients with advanced chronic lymphocytic leukemia. Previously, good tolerance of the preparation had been found in 49 immunologically normal patients. The four patients with secondary humoral immunodeficiency received doses of 140-360 mg IgG/kg per infusion as outpatients at monthly intervals. With one exception, no acute infections (pneumonitis), as commonly seen before, were observed during the observation time of 24 to 68 weeks, and the pre-existing chronic infections (bronchitis, sinusitis etc.) remained compensated without antibiotics. In all four patients tolerance of the preparation was good. In all cases of hypogammaglobulinemia a dose-dependent increase in the serum IgG concentration was observed immediately after the infusion. However, persistence of the serum IgG increase showed considerable interindividual differences. The half life of the tetanus and HBs antibodies (21.7 to 34.4 and 19.7 to 25.7 days respectively) found in 4 healthy volunteers is within the biological range. This indicates an unmodified structure of the antibodies of the IgG class contained in the preparation used.
 ...
PMID:[Tolerability and pharmacokinetics of an intravenous immunoglobulin preparation in immunologically normal subjects and tolerability in patients with hypogammaglobulinemia resulting from chronic lymphatic leukemia]. 351 30

Pneumonia, acute bronchitis, and sinusitis are common infections encountered by the pulmonary specialist. Such conditions are usually treated with antibiotics, and their use requires an understanding of their pharmacokinetic properties as well as their antimicrobial spectrum and adverse side effects.
 ...
PMID:Respiratory pharmacology. Antibiotics. I. Beta-lactam antibiotics, the tetracyclines, chloramphenicol, erythromycin, clindamycin, metronidazole, and the quinolones. 353

The efficacy of ceftriaxone, 1 g given intramuscularly once daily, was evaluated in 38 patients with pneumonia (n = 11), pulmonary empyema (n = 2), bronchitis (n = 4), tonsillitis (n = 9), sinusitis (n = 7), and otitis (n = 5). Causative organisms were Streptococcus pneumoniae (n = 11), viridans type streptococcus (n = 1), Haemophilus influenzae (n = 6), group A streptococcus (n = 10), Staphylococcus aureus (n = 3), Klebsiella pneumoniae (n = 2), Pseudomonas aeruginosa (n = 1), Escherichia coli (n = 2), Proteus mirabilis (n = 1), and Proteus vulgaris (n = 1). Sterilization of infected foci was obtained in 89.4% of those treated, with clinical recovery in 86.8%. The ceftriaxone regimen was well tolerated.
 ...
PMID:Ceftriaxone therapy in otolaryngological and pulmonary infections. 370 68

The efficacy and safety of cefadroxil in the treatment of paediatric patients with a wide variety of infections were evaluated in a multicentre clinical trial. This study included 395 infants and children with Group A streptococcal pharyngitis, sinusitis, otitis media, bronchitis, pneumonia or bronchopneumonia, urinary tract infections and acute gastroenteritis. Cefadroxil was given as a suspension in a daily dose of 30 to 50 mg/kg in 2 divided doses every 12 hours to all but 76 patients; 50 patients with acute otitis media were given 100 mg/kg/day in 2 doses and 26 patients with urinary tract infections received 25 mg/day once daily. Of 317 patients with respiratory tract infections and 78 with urinary or gastrointestinal infections, 95 and 100%, respectively, were clinically cured following treatment with cefadroxil.
 ...
PMID:Cefadroxil in the treatment of susceptible infections in infants and children. 380 50

An epidemiological survey of 3216 primary school children living in the industrial, urban and rural areas of Singapore revealed a high prevalence of various respiratory symptoms and illnesses, with 13.1% cough, 8.2% wheezy chest, 25.9% blocked/running nose, 4.3% sinusitis, 7.8% asthmatic attacks and 4.1% bronchitis/pneumonia. Differences in the prevalence of respiratory illnesses and lung function tests were observed among children in the three areas, but this could not be accounted for by the varying air pollution levels which have been maintained below the long-term standards set up by WHO. It was probably responsible for the differences noted.
 ...
PMID:Prevalence of respiratory illnesses of school children in the industrial, urban and rural areas of Singapore. 381 Aug 38

Seven-day courses of either 200 mg pivmecillinam plus 250 mg pivampicillin or co-trimoxazole (800 mg sulphamethoxazole plus 160 mg trimethoprim) given twice daily were compared in a multi-centre general practice study in 318 patients with signs and symptoms of upper or lower respiratory tract infection. Patients were stratified into four diagnostic groups (sinusitis, otitis media, throat infections, and acute bronchitis) and randomly allocated to treatment within these groups. Assessments at Day 7 showed that both treatments were equally effective clinically, 154 (91%) patients in the pivmecillinam plus pivampicillin group showing clinical cure or improvement and 142 (88%) patients in the co-trimoxazole group. Side-effects were reported by 19 (11.9%) patients in the pivmecillinam plus pivampicillin group and by 24 (15.8%) patients in the co-trimoxazole group. Two patients in the pivmecillinam plus pivampicillin group and 4 patients in the co-trimoxazole group stopped treatment.
 ...
PMID:A multi-centre general practice clinical evaluation of pivmecillinam plus pivampicillin ('Miraxid') and co-trimoxazole ('Septrin') in respiratory tract infections. 390 87


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>